Nemonapride

Nemonapride

SCHEMBL31320714

[2H]C([2H])([2H])Oc1cc(NC)c(Cl)cc1C(=O)N[C@@H]1CCN(Cc2ccccc2)[C@@H]1C

nearest known ligand 0.88

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DRD4 P21917 18/20 0.88
▸ DRD3 P35462 15/20 0.88
▸ DRD2 P14416 14/20 0.88
▸ NR1I2 O75469 1/20 0.88
▸ ADRB2 P07550 1/20 0.88
▸ ADRB1 P08588 1/20 0.88
▸ HTR1A P08908 1/20 0.88
▸ ADRA2A P08913 1/20 0.88
▸ ADORA3 P0DMS8 1/20 0.88
▸ ADRA2B P18089 1/20 0.88
▸ ADRA2C P18825 1/20 0.88
▸ CHRM3 P20309 1/20 0.88
▸ SLC6A2 P23975 1/20 0.88
▸ HTR2A P28223 1/20 0.88
▸ HTR2C P28335 1/20 0.88
▸ SLC6A4 P31645 1/20 0.88
▸ ADRA1A P35348 1/20 0.88
▸ HRH1 P35367 1/20 0.88
▸ OPRD1 P41143 1/20 0.88
▸ OPRK1 P41145 1/20 0.88

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nemonapride SCHEMBL50209 0.94 DRD4 (1.00) DRD4DRD3DRD2NR1I2ADRB2
Nemonapride SCHEMBL50208 0.94 DRD4 (1.00) DRD4DRD3DRD2NR1I2ADRB2
Nemonapride SCHEMBL1649724 0.94 DRD4 (1.00) DRD4DRD3DRD2NR1I2ADRB2
Nemonapride SCHEMBL30442102 0.94 DRD4 (1.00) DRD4DRD3DRD2NR1I2ADRB2
Nemonapride SCHEMBL29387146 0.94 DRD4 (1.00) DRD4DRD3DRD2NR1I2ADRB2
Nemonapride SCHEMBL25247691 0.94 DRD4 (1.00) DRD4DRD3DRD2NR1I2ADRB2
Nemonapride SCHEMBL8824385 0.93 DRD4 (0.98) DRD4DRD3DRD2NR1I2ADRB2
Nemonapride SCHEMBL11462830 0.93 DRD4 (0.98) DRD4DRD3DRD2NR1I2ADRB2
Nemonapride SCHEMBL31427577 0.85 DRD4 (0.78) DRD4DRD3DRD2NR1I2ADRB2
Nemonapride SCHEMBL31544766 0.85 DRD4 (0.78) DRD4DRD3DRD2NR1I2ADRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260098011-A1 DEUTERATED ORGANIC COMPOUNDS AND USES THEREOF ENGRAIL THERAPEUTICS INC (US) 2026-04-09 — — US disclosed
US-12365650-B2 Deuterated organic compounds and uses thereof ENGRAIL THERAPEUTICS, INC. (US) 2025-07-22 — — US disclosed
US-20250011279-A1 DEUTERATED ORGANIC COMPOUNDS AND USES THEREOF ENGRAIL THERAPEUTICS, INC. 2025-01-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12365650-B2 Deuterated organic compounds and uses thereof DRD2, DRD1, DRD4 DRD4 3/4885DRD3 12/4885DRD2 1/4885
US-20260098011-A1 DEUTERATED ORGANIC COMPOUNDS AND USES THEREOF SLC6A3, DRD2, SLC6A2 DRD4 7/4885DRD3 9/4885DRD2 2/4885
US-20250011279-A1 DEUTERATED ORGANIC COMPOUNDS AND USES THEREOF DRD2, DRD1, DRD4 DRD4 3/4885DRD3 12/4885DRD2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback